Related Experiment Video
Updated: Aug 4, 2026

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation
Published on: April 14, 2016
[Treatment of bone disorders in renal diseases]
Aim:
To study possible correction of bone disorders (osteopenia, Ca/P-imbalance, bone pain, limited volume of indolent movements) which are still a serious complication associated with renal diseases and pathogenic therapy (steroids).
Materials And Methods:
The bone disorders were treated in 10 uremic hemodialyzed patients (8 men, 2 women; group 1) with vitamin D3 (calcitriol made in Russia) + rhEPO (recormon; Boehringer Mannheim), in 15 patients (15 women, 0 men) with lupus-nephritis (group 2) with vitamin D3 (n = 5, group 2a) or miscalcic (Sandoz) (n = 10, group 2b), in 2 patients (2 men, 0 women) with glomerulonephritis (group 3) with vitamin D3 + miacalcic. Additionally all the patients received Ca salts. In groups 2 and 3 renal function was normal. The duration of the treatment was 3-6 months.
Results:
In all the groups we obtained an analgetic effect (attenuation of bone pain and more indolent movements), improvement of life quality, diminished need in analgetics, elevation of serum Ca level (p > 0.05).
Conclusion:
Treatment of renal patients with bone affection with vitamin D3 and miacalcic has an analgetic effect, improves life quality.
Related Concept Videos
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Urinary Tract Calculi III: Medical Management
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Acute Kidney Injury V: Interprofessional Care
Chronic Kidney Disease III: Interprofessional Care

